Viewpoint
Why as a Medicinal Chemist I Am Not Optimistic about the Possibility of Finding, in a Reasonable Timeframe, Small-Molecule Drugs Capable of Curing the Evolution of Alzheimer’s Disease
Article first published online: 11 OCT 2011
DOI: 10.1002/cmdc.201100431
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Issue

ChemMedChem
Special Issue: Neuroscience Drug Discovery
Volume 7, Issue 3, pages 357–358, March 5, 2012
Additional Information
How to Cite
Kraus, J.-L. (2012), Why as a Medicinal Chemist I Am Not Optimistic about the Possibility of Finding, in a Reasonable Timeframe, Small-Molecule Drugs Capable of Curing the Evolution of Alzheimer’s Disease. ChemMedChem, 7: 357–358. doi: 10.1002/cmdc.201100431
Publication History
- Issue published online: 1 MAR 2012
- Article first published online: 11 OCT 2011
- Manuscript Received: 14 SEP 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- Alzheimer’s disease;
- brain matter structure
Abstract
Herein I explain why I feel that new and effective Alzheimer′s disease (AD) drugs cannot emerge from current developed concepts such as the amyloid pathway, or acetylcholinesterase inhibitors. The discovery of new therapeutic approaches first requires an understanding of the intimate structure of brain matter, where memory and cognition are located, and how aging alters its structure and function. Only by joining the expertise of quantum physicists and physical chemists with that of medicinal chemists, pharmacologists, biologists and medical doctors can new AD research orientations emerge.

1860-7187/asset/2452_left.gif?v=1&s=4110e7425ac5e40773dfb0778cfefa62f1594507)
1860-7187/asset/2452_right.gif?v=1&s=8458ea1f15af84217b579501ed7d7733bef04a94)